Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.

Shares of Quest Diagnostics Inc. DGX rallied 2.27% to $175.56 Friday, on what proved to be an all-around great trading ...

A Wall Street analyst issued contrasting ratings on Tuesday for two major diagnostic testing companies, upgrading shares of ...

Citi downgraded Quest Diagnostics (DGX) to Neutral from Buy with an unchanged price target of $185. The firm believes Quest is well positioned ...

DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.

In an age of capitation and value-based care, health plans must work harder than ever to offer tailored support to higher-risk members with chronic conditions.

Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical Care—including services that Quest will then provide back to Fresenius as | The assets ...

Fresenius Medical Care plans to sell select assets of Spectra Laboratories to Quest Diagnostics as it exits non-core markets.

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, recently announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® ...

Quest Diagnostics Inc. DGX benefits from its robust utilization of the Advanced Diagnostics portfolio offerings. The company also expands through strategic acquisitions, completing eight transactions ...

Fresenius Medical Care announced today that it agreed to sell select assets of its laboratory testing services to Quest ...

In a separate agreement, Quest will provide lab services for end-stage kidney disease and specialized water testing for Fresenius and its partners.